Feedback
Settings

Settings

Goto Application

1,575 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

PUBLICATION_DATE=2007
1 / 158
1.WO/2007/106534SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES
WO - 20.09.2007
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/US2007/006442 Applicant HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE Inventor KOLODNEY, Michael, S.
In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These 'blocker' probes can be used in combination with longer 'detection' probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes.
2.WO/2007/058894SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
WO - 24.05.2007
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/US2006/043651 Applicant THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Inventor SAZANI, Peter, L.
Methods and compositions are disclosed for controlling expression of TNF receptors (TNFRl and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-α activity or activity of the relevant ligand. Reducing TNF-α activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-α activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H.
3.1923790Kutkin derivative, preparation method and application thereof
CN - 07.03.2007
Int.Class C07C 69/035
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
69Esters of carboxylic acids; Esters of carbonic or haloformic acids
02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
035esterified with a hydroxy compound having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
 Appl.No 200610037302.1 Applicant Jinan University Inventor Jiang Jie
The invention discloses a derivant of kutkin with chemical structural formula as formula I, wherein R1 is NO2, NH2 or amide; R2 is H, carbonyl or diaminocarbonyl. The preparing method comprises the following steps: nitrating kutkin to obtain kutkin derivant substituted by nitro group or kutkin derivant based on substituted nitro group; or kutkin derivant substituted by acetylamino.
4.WO/2007/103586PROCESS FOR THE PRODUCTION OF ANHYDROSUGAR ALCOHOLS
WO - 13.09.2007
Int.Class C07D 493/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
493Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02in which the condensed system contains two hetero rings
06Peri-condensed systems
 Appl.No PCT/US2007/006185 Applicant ARCHER-DANIELS-MIDLAND COMPANY Inventor SANBORN, Alexandra, J.
A process is provided for the preparation of anhydrosugar alcohols. The process involves heating a sugar alcohol or a monoanhydrosugar alcohol starting material in the presence of an acid catalyst and under pressure. Optionally the resulting product is purified. Very high purities are achieved, without necessitating the use of organic solvents in the process.
5.WO/2007/141700MICROELECTRONIC SENSOR DEVICE FOR DNA DETECTION
WO - 13.12.2007
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
 Appl.No PCT/IB2007/051960 Applicant KONINKLIJKE PHILIPS ELECTRONICS N. V. Inventor VOSSENAAR, Erik Robbert
The invention relates to a microelectronic sensor device and a method for the investigation of biological target substances (20), for example oligonucleotides like DNA fragments. In one embodiment, the device comprises a reaction surface (RS) to which target specific reactants (10) are attached and which lies between a sample chamber (SC) and an array of selectively controllable heating elements (HE). The temperature profile in the sample chamber (SC) can be controlled as desired to provide for example conditions for a PCR and/or for a controlled melting of hybridizations. The reactant (10) and/or the target substance (20) comprises a label (12) with an observable property, like fluorescence, that changes if the target substance (20) is bound to the reactant (10), said property being detected by an array of sensor elements, for example photosensors (SE). The fluorescence of the label (12) may preferably be transferred by FRET to a different fluorescent label (22) or quenched if the target substance (20) is bound.
6.WO/2007/060486TREATMENT OF NEURODEGENERATIVE DISORDERS
WO - 31.05.2007
Int.Class A61K 38/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
06Tripeptides
 Appl.No PCT/GB2006/050414 Applicant THE OPEN UNIVERSITY Inventor ROSE, Steven, Peter, Russell
Peptides having the sequence D-Arg-L-Glu-L-Arg, or the sequence L-Arg-D-Glu-L-Arg and derivatives thereof, are disclosed. Such peptides are useful in treatment of neurodegenerative disorders, and as cognitive enhancers. Preferred peptides include a protective group.
7.WO/2007/014379A LIPIDIC EXTRACT FROM LEPIDIUM MEYNII AND ITS EFFECT ON THE LIBIDO
WO - 01.02.2007
Int.Class A61K 36/31
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
 Appl.No PCT/US2006/029720 Applicant NATUREX Inventor ZHENG, Qun Yi
The present invention relates to compositions containing particular components that can be obtained from a plant which can have pharmaceutical applications. More particularly, the plant genus is Lepidium and the composition may contain in the range of between about .3% and .7% of benzyl isothiocyanate, b) between about .06% and about .02% of Lepidium sterol component, c) between about 1% and about 2% of a Lepidium fatty acid component, and d) about .006% to .6% or more total macamide/macaenes component as standardized with excipients.
8.20070213544Process for the production of anhydrosugar alcohols
US - 13.09.2007
Int.Class C07D 307/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
307Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
 Appl.No 11716277 Applicant Archer-Daniels-Midland Company Inventor Sanborn Alexandra J.

A process is provided for the preparation of anhydrosugar alcohols. The process involves heating a sugar alcohol or a monoanhydrosugar alcohol starting material in the presence of an acid catalyst and under pressure. Optionally the resulting product is purified. Very high purities are achieved, without necessitating the use of organic solvents in the process.

9.20070225374Hydroxypropyl Amides for the Treatment of Alzheimer's Disease
US - 27.09.2007
Int.Class A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
 Appl.No 10575824 Applicant ELAN PHARMACEUTICALS, INC. Inventor Tucker John

The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation. embedded image

10.20070116786A LIPIDIC EXTRACT FROM LEPIDIUM MEYNII AND ITS EFFECT ON THE LIBIDO
US - 24.05.2007
Int.Class A61K 36/185
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
 Appl.No 11460142 Applicant NATUREX Inventor Zheng Qun Yi

The present invention relates to compositions containing particular components that can be obtained from a plant which can have pharmaceutical applications. More particularly, the plant genus is Lepidium and the composition may contain in the range of between about 0.3% and 0.7% of benzyl isothiocyanate, b) between about 0.06% and about 0.02% of Lepidium sterol component, c) between about 1% and about 2% of a Lepidium fatty acid component, and d) about 0.006% to 0.6% or more total macamide/macaenes component as standardized with excipients.

# -